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Clinical Outcome After First and Recurrent Hemorrhage in
Patients With Untreated Brain Arteriovenous Malformation
Jae H. Choi, MD; Henning Mast, MD; Robert R. Sciacca, EngScD; Andreas Hartmann, MD;
Alexander V. Khaw, MD; Jay P. Mohr, MD; Ralph L. Sacco, MD; Christian Stapf, MD
Background and Purpose—The morbidity from spontaneous hemorrhage of untreated brain arteriovenous malformations
(AVM) is not well described.
Methods—The 241 consecutive AVM patients (mean age 3716 years, 52% women) from the prospective Columbia
AVM Databank initially presenting with hemorrhage were evaluated using the Rankin Scale (RS) and the National
Institute of Health Stroke Scale (NIHSS). From the 241 AVM patients, 29 (12%) had subsequent intracranial
hemorrhage during follow-up. For further comparisons, 84 non-AVM patients with intracerebral hemorrhage from the
Northern Manhattan Study (NOMAS) served as a control group.
Results—In 241 AVM patients presenting with hemorrhage the median RS was 2 and the median NIHSS was 1 (49% RS
0 to 1, 61% NIHSS 2). The median time between hemorrhage and clinical evaluation was 11 days (mean 219 days).
Recurrent AVM hemorrhage during follow-up resulted in no significant increase in morbidity (median RS 2, P0.004;
median NIHSS 3, P0.322; time between hemorrhage and study evaluation: median 55 days, mean 657 days). Among
AVM-hemorrhage subtypes, parenchymatous AVM hemorrhage was associated with higher stroke morbidity (odds
ratio, 2.9; 95% CI, 1.5 to 5.8 for NIHSS2) than nonparenchymatous hemorrhages. Parenchymatous AVM hemorrhage
had a significantly better outcome (median NIHSS 1) than non-AVM related hemorrhage (median NIHSS 12;
P0.0001).
Conclusions—Hemorrhage, either at initial presentation or during follow-up of untreated AVM patients appears to carry
a lower morbidity than intracranial hemorrhage from other causes. These findings support a careful weighing of risks
from interventional treatment and natural history. (Stroke. 2006;37:1243-1247.)
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Up to 2% of all intracranial hemorrhages are caused byruptured brain arteriovenous malformations (AVM).1,2 De-
spite this small proportion, AVM are gaining more attention
because of the more frequent use of noninvasive imaging
methods, like brain MRI, which is uncovering an increasing
number of such malformations, bled and unbled.3 Population-
based studies reveal that about 35% to 50% of patients with
AVM initially present with hemorrhage, and the annual risk of
further hemorrhage may vary from 1% to 18%.1,4–9 Modern
invasive treatment methods have been developed with the aim at
eliminating this source of hemorrhage, comprising microsurgical
resection, endovascular embolization, radiotherapy, alone or in
combination.10 However, the risk of invasive therapy needs to be
weighed against the natural history hazard of untreated AVM.
Although intracranial hemorrhage is generally considered to consti-
tute a possibly devastating event, prior series suggest that AVM
hemorrhage may be more benign than previously assumed.11–17
To address this issue, we sought to determine the short- and
the long-term neurological outcome in patients with untreated
AVM after first and recurrent hemorrhage and to compare
their outcome with a control sample of non-AVM–related
intracerebral hemorrhage cases.
Patients and Methods
The Columbia University Medical Center is a tertiary referral center
recruiting patients with AVM from the local New York Metropolitan
area and distant referral sites. The Columbia AVM Database is an
ongoing prospective study project with consecutive enrollment since
1989. The aim of this observational study is to collect demographic,
clinical, morphological, and treatment data of patients with AVM
admitted to our center for diagnosis and treatment. All AVM have
been diagnosed based on brain imaging and cerebral angiography.
The Columbia AVM Databank design conforms to the national
consensus recommendations for AVM research reporting terminol-
ogy and have been described in prior publications.8,15,16,17 This
analysis includes patients enrolled in the Columbia AVM Database
until August 2004.
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Hemorrhagic AVM presentation was defined as a symptomatic
clinical event with signs of fresh intracranial blood on head CT or
MRI or in the cerebrospinal fluid, leading to the diagnosis of a AVM.
Recurrent hemorrhage was defined as a new symptomatic follow-up
event attributable to AVM rupture, confirmed by brain imaging.
Morphological variables were grouped into AVM location (lobar,
deep, infratentorial, and borderzone), drainage pattern (drainage into
superficial veins, combined drainage into deep and superficial veins,
or into deep veins only), and AVM size (in mm). Concurrent arterial
aneurysms were defined as saccular dilatations of the lumen 2
times the width of the arterial vessel that carried the dilatation. They
were further classified as feeding artery aneurysms, intranidal
aneurysms (both considered AVM-associated), and aneurysms unre-
lated to blood flow to the AVM (nonassociated aneurysms).18
Infundibula, arterial ectasias (ie, dilated feeding vessels), and in-
tranidal aneurysmal dilatations seen during the venous angiographic
phase only were not coded as arterial aneurysms. Arterial aneurysms
were coded as unrelated to the AVM when located on intracranial
arteries not contributing blood flow to the malformation.
Hemorrhagic stroke severity and clinical outcome after each
hemorrhagic event were measured using the National Institute of
Health Stroke Scale (NIHSS) and Rankin Scale (RS). In our analysis,
clinical assessment was stratified into favorable (NIHSS score 0 to 1)
and unfavorable (NIHSS score 2) neurological outcome.
After the initial hemorrhagic event, only untreated patients were
included in the analysis. Follow-up data after hemorrhage as well as
the last available data before lesion-targeted treatment were evalu-
ated. Patients were censored at initiation of treatment aiming at
AVM obliteration or elimination (date of first embolization, radio-
therapy, or surgery).
Predominant anatomical bleeding location, categorized into non-
parenchymatous (subarachnoid or ventricular) or parenchymatous
hemorrhage, was further tested for its effect on outcome severity.
In addition, outcome after parenchymatous AVM bleeds was com-
pared with outcome data of survivors after non-AVM–related intrace-
rebral hemorrhages from the Northern Manhattan Study (NOMAS)
incidence dataset.19 NOMAS is a prospective, population-based epide-
miological study in a multiethnic population and aims at determining
stroke incidence, risk factors for stroke, and functional outcome. All
NOMAS patients were evaluated within 30 days after incident
intracerebral hemorrhages. For direct outcome comparisons, we
included only AVM patients with parenchymatous hemorrhages and
documented neurological assessment within 30 days after the index
event.
Univariate statistical models were applied to test the effect of
hemorrhage location on outcome severity (Wilcoxon Rank Sum test
and 2 test/Fisher exact test). Outcome comparisons between inci-
dent and recurrent AVM hemorrhage, and between the Columbia
AVM Database and the NOMAS cohort were analyzed using the
Wilcoxon Rank Sum test and Two Sample test, and 2 test/Fisher
exact test (level of significance 0.05, respectively). A multivar-
iate logistic regression model was used to test the effect of demo-
graphic factors, AVM size, and hemorrhage location on neurological
outcome in patients with early outcome assessment (30 days after
the index event).
Results
Clinical Outcome After Incident AVM
Hemorrhage in Untreated AVM Patients
Overall, 241 AVM patients were clinically evaluated after the
hemorrhage event by an independent study neurologist. Baseline
characteristics of the study cohort are shown in Table 1.
RS scores were available for all 241 patients, NIHSS scores
for 233. The median delay between AVM rupture and initial
neurological assessment was 11 days (mean 219 days). Outcome
results are summarized in Table 2: 119 patients (49%) had RS
scores 1 and 34 patients (14%) had RS scores of 4 or 5; 142
patients (61%) were ranked at NIHSS scores of 0 to 1 and 11
patients (5%)13. Parenchymatous AVM hemorrhage resulted
in significantly higher NIHSS scores than subarachnoid or
intraventricular hemorrhage (P0.001), whereas no significant
differences were seen for RS score comparisons (Table 3). By
multivariate testing, parenchymatous AVM hemorrhage was an
independent predictor for unfavorable outcome (NIHSS score
2; Table 4), whereas age, gender, race, and AVM size showed
no significant effect.
Clinical Outcome After Follow-Up AVM
Hemorrhage in Untreated AVM Patients
During natural history follow-up (median 55 days, mean 657
days) subsequent AVM hemorrhage occurred in 29 patients
(12%). Neurological outcome as measured by the NIHSS was
similar (median NIHSS 3, mean NIHSS 5.78.4) compared
with the incident hemorrhage event (median NIHSS 1, mean
NIHSS 3.66.2; P0.322), but disability measured by the
RS was worse (follow-up hemorrhage: median RS 2, mean
RS 2.71.4; incident hemorrhage: median RS 2, mean RS
2.01.4; P0.004). One patient died after the recurrent
bleed. Clinical improvement after first or recurrent hemor-
rhage over time was observed in 40% and 39% (worsening in
2% and 4%) measured by RS score and by NIHSS subcate-
gories, respectively.
TABLE 1. Demographic and Morphological Characteristics
of 241 Untreated AVM Patients With Hemorrhage at
Initial Presentation
Age, meanSD (y) 3716
Female gender 125 (52%)
Max AVM diameter, meanSD (mm) 26.415.5
Location
Lobar 171 (71%)*
Deep 46 (19%)
Infratentorial 41 (17%)
Borderzone 70 (29%)
Drainage
Superficial 102 (42%)
Deep and superficial 62 (26%)
Deep only 77 (32%)
Aneurysm
Any intracranial 75 (31%)
Flow-related 46 (19%)
Intranidal 22 (9%)
Hemorrhage location
Parenchymatous 171 (71%)
Subarachnoid 36 (15%)
Ventricular 34 (14%)
*Total No. exceeds n241 attributable to overlapping lobar and deep AVM
topography in 17 (7%) cases.
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Comparison of Clinical Outcomes Between
Parenchymatous AVM Hemorrhage and
Non-AVM–Related Intracranial Hemorrhage
A total of 160 AVM patients (66%) had their first clinical
examination within 30 days after the initial hemorrhagic
event (median delay time 3 days, mean 7 days; Table 2) with
a median RS score of 2 (mean 21.5) and a median NIHSS
score of 1 (mean 3.66.3). Among these 160 patients, 114
(71%) experienced parenchymatous AVM hemorrhage and
were compared with the 84 survivors of non-AVM–related
intracerebral hemorrhage from NOMAS. By univariate com-
parison, AVM patients were significantly younger, more
likely to be of white origin, and showed significantly better
clinical outcome (median NIHSS 1) than the NOMAS pa-
tients (median NIHSS 12; P0.0001; Table 5).
Discussion
Intracranial hemorrhage constitutes the most feared compli-
cation of AVMs and has been considered to carry a high
burden of morbidity and mortality. A longitudinal series from
Finland, conducted before the modern imaging era, found that
23% of 166 untreated patients experienced major morbidity
or death from AVM hemorrhage.14 In a retrospective single
center study published in 1984, Fults and Kelly observed 83
AVM patients during a mean follow-up time of 8.7 years,
including 62% who presented with hemorrhage; of the latter,
40.5% died during follow-up because of the initial or recur-
rent bleeding.11 In a retrospective population-based study by
Brown et al, the 168 AVM patients included showed a 2.25%
annual hemorrhage rate with an associated mortality of 29%;
the risk of severe disability among hemorrhage survivors was
23%.13 A mixed retrospective and prospective study of 240
AVM patients from Australia suggested 24.6% of conserva-
TABLE 2. Incident and Recurrent AVM Hemorrhage
in Untreated AVM Patients
RS
Incident
Hemorrhage
Subgroup of the
Columbia Cohort With
30-Day Evaluation
Recurrent
Hemorrhage
MeanSD 21.4 21.5 2.71.4
Median 2 2 2
n (%) n (%) n (%)
0 42 (17%) 25 (16%) 0
1 77 (32%) 39 (24%) 7 (24%)
2 56 (23%) 44 (28%) 9 (31%)
3 32 (13%) 20 (13%) 6 (21%)
4 17 (7%) 16 (10%) 3 (10%)
5 17 (7%) 16 (10%) 4 (14%)
Total 241 (100%) 160 (100%) 29 (100%)
NIHSS
MeanSD 3.66.2 3.66.3 5.78.4
Median 1 1 3
n (%) n (%) n (%)
0 to 1 142 (61%) 87 (57%) 9 (31%)
2 to 3 39 (17%) 23 (15%) 6 (21%)
4 to 5 16 (7%) 12 (8%) 4 (14%)
6 to 7 9 (4%) 8 (5%) 3 (10%)
8 to 9 8 (3%) 6 (4%) 2 (7%)
10 to 11 6 (2%) 5 (3%) 1 (3%)
12 to 13 2 (1%) 5 (3%) 1 (3%)
13 11 (5%) 12 (8%) 3 (10%)
Missing 8 (3%) 2 (1%)
Total 241 (100%) 160 (100%) 29 (100%)
TABLE 3. Effect of Anatomic Bleeding Location on Outcome After Hemorrhagic AVM Presentation in Untreated
AVM Patients and for the Subgroup With 30-Day Evaluation
Entire Columbia AVM-Cohort
Subgroup of the Columbia AVM-Cohort With
30-Day Evaluation
RS n (%) MeanSD* Median n (%) MeanSD‡ Median
Ventricular 30 (12%) 1.41.1 1 16 (10%) 1.41.1 1
Parenchymatous 170 (71%) 1.91.4 2 114 (71%) 2.11.5 2
Subarachnoid 32 (13%) 1.91.6 1 25 (16%) 2.11.7 1
NIHSS n (%) MeanSD† Median n (%) MeanSD§ Median
Ventricular 30 (13%) 0.71.2† 0 16 (10%) 0.50.9† 0
Parenchymatous 163 (70%) 3.45.8† 1 114 (71%) 3.96.1† 1
Subarachnoid 32 (14%) 2.66.3† 1 25 (16%) 3.57.1† 1
Kruskal-Wallis Test: *P0.304; †P0.001; ‡P0.242; §P0.01.
For the NIHSS, data only from 233 patients were available. For patients with undetermined bleeding location (n9) no RS or NIHSS
scores are given.
TABLE 4. Multiple Logistic Regression Model* Testing the
Effect of Age, Gender, Race/Ethnicity, AVM Diameter, and
Parenchymatous Hemorrhage Location on Unfavorable Outcome
(NIHSS >2) in n241 Patients With AVM-Hemorrhage
Odds Ratio 95% CI
Age (y) 1.0 0.98 to 1.02
Female gender 0.9 0.53 to 1.61
Race/ethnicity (white) 1.1 0.78 to 1.43
Max AVM diameter (mm) 1.0 0.99 to 1.05
Parenchymatous hemorrhage 2.9† 1.53 to 5.82
*Interaction terms included in the model are not significant: age-female;
age-race; diameter-age; par_hem-age; par_hem-female; par_hem-race;
par_hem-diameter. †P0.005.
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tively managed patients die of AVM hemorrhage within an
average of 10 years from diagnosis, and 27% of the survivors
remained severely disabled (RS score 3).5 Finally, a recent
retrospective analysis of hospital discharge data suggested
33% of patients experiencing AVM hemorrhage had major
neurological impairment with a RS score 3.20
In contrast to the figure cited above, a few prior series
suggested that outcome after AVM rupture might actually be
more benign: in a retrospective analysis, Crawford et al
reported an overall mortality rate of 1.5% per year (1.6% for
those after initial hemorrhage) and an annual rate of severe
morbidity of 1.4%.12 In a previous smaller patient sample
from the Columbia AVM Database (115 patients after AVM
hemorrhage with neurological assessment, mean follow-up
time 1.35 years) only 7% were assigned RS scores of 4 or 5
after first and subsequent bleeding event.17 The proportion of
asymptomatic patients (RS 0) was 47%, an additional 37%
remained independent in their daily activities (RS 1).
Our own findings argue in favor of a relatively low
morbidity after incident AVM hemorrhage with an average
RS score of 2 at the time of the initial AVM rupture. Further,
neurological impairment was mainly determined by paren-
chymatous AVM bleeding with an almost 3-fold increased
risk for unfavorable outcome compared with nonparenchy-
matous hemorrhage. However, when compared with patients
after non-AVM–related intracerebral hemorrhage, AVM pa-
tients with intraparenchymatous bleeding still had signifi-
cantly better outcomes.21,22,23
Twelve percent of our untreated patients experienced
recurrent AVM hemorrhage during an average follow-up of
1.8 years, leading to a crude annual rebleeding rate of 7%.
This supports prior findings showing relatively high rerupture
rates in patients after hemorrhagic AVM presentation, espe-
cially during the first year after the index event.16,20 However,
in our sample recurrent AVM hemorrhage did not alter
clinical outcome and carried a low mortality.
The outcome comparison between the Columbia AVM
Database and the NOMAS incidence cohort carries some
methodological limitations: the majority of cases in NOMAS
were evaluated within the first 3 days after their stroke. With
an average delay of 7 days (median 3 days) between index
event and first clinical assessment for the AVM cohort, we
cannot exclude the possibility of a systematic bias. Whereas
AVM (ruptured and unruptured) are mainly found in a
relatively young population (3rd decade of life), subarachnoid
hemorrhage and non-AVM–related intracerebral hemorrhage
(4th/5th decade and older) occur in a significantly older
population. Also, the distribution of gender and risk factors
for hemorrhage differ between those entities. Table 5 sum-
marizes further demographic differences between the 2 study
samples: the mean age of the NOMAS-cohort was signifi-
cantly higher (6515 versus 3716; P0.0001) and the
proportion of nonwhite individuals was significantly higher
in the NOMAS cohort (76% versus 30%; P0.0001). Al-
though the effect of race/ethnicity on AVM natural history
remains as yet unknown,10 the significantly younger age
among AVM patients may act as a confounder when com-
paring outcome with non-AVM–related hemorrhage. Also,
comorbidity was not systematically coded in the Columbia
AVM Databank; hence, no further baseline comparisons with
the more elderly NOMAS cohort could be undertaken.
The AVM patient sample is drawn from a large prospective
dataset, but attributable to as yet unknown population-based
case fatality rates after AVM hemorrhage, referral center
cohorts such as ours may underestimate the overall frequency
of incident AVM hemorrhage and associated risk factors.1,4 In
addition, referral bias to specialized treatment centers may
influence demographic and clinical characteristics of local
patient cohorts. The possibility of systematic or random error
in the data analysis can therefore not be excluded and our
results will need confirmation from the currently ongoing
population-based studies.8,7
Prior studies have generally not included report on the delay
of clinical assessment after the bleeding event. The time-
dependent inclusion criteria as used in our analysis (neurological
evaluation within 30 days after the index event) is more likely to
reveal the actual impact of hemorrhage after AVM rupture. The
results of the present study support assumptions, that not only
the course, but also the clinical presentation after hemorrhages
attributable to AVM-rupture seem to be milder when compared
with non-AVM–related intracerebral hemorrhage. This effect
may be explained in part by the relatively younger age, different
premorbid characteristics, lower AVM leakage pressure and
bleeding into the AVM nidus itself without major disruption of
actual brain tissue.
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TABLE 5. Comparison of Demographic and Clinical
Characteristics in Patients After AVM- and Non-AVM–Related
Parenchymatous Hemorrhage (Clinical Assessment <30 Days
After Index Event)
AVM-related
Parenchymatous
Hemorrhage
n114
Non AVM-related
Parenchymatous
Hemorrhage
n84 P
Age, mean (SD) 35 (15) 65 (15) 0.0001*
Female gender 54 (47%) 46 (55%) 0.304†
Race/ethnicity
White 78 (68%) 20 (24%) 0.001†
Black 7 (6%) 21 (25%)
Hispanic 23 (20%) 43 (51%)
Asian 6 (5%) 0
Outcome (NIHSS)
MeanSD 3.96.2 13.69.5 0.0001*
Median 1 12 0.0001
0 to 5 83 (73%) 20 (24%)
6 to 13 19 (17%) 28 (33%) 0.0001†
13 6 (5%) 36 (43%)
*Wilcoxon Two Sample test; †2 test.
For 6 (5%) AVM patients no NIHSS scores were available.
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